Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02124772
Title Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: child
Covered Countries USA | GBR | FRA | CAN | AUS

Facility Status City State Zip Country Details
Novartis Investigative Site Phoenix Arizona 85016-7710 United States Details
Novartis Investigative Site San Francisco California United States Details
Novartis Investigative Site Washington District of Columbia 20010 United States Details
Novartis Investigative Site Baltimore Maryland 21287 United States Details
Novartis Investigative Site Boston Massachusetts 02115 United States Details
Novartis Investigative Site Minneapolis Minnesota 55455 United States Details
Novartis Investigative Site New York New York 10065 United States Details
Novartis Investigative Site Cincinnati Ohio 45229 United States Details
Novartis Investigative Site Philadelphia Pennsylvania 19104 United States Details
Novartis Investigative Site Memphis Tennessee 38105-3678 United States Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Toronto Ontario M5G 1X8 Canada Details
Novartis Investigative Site Paris Cedex 05 75248 France Details
Novartis Investigative Site Villejuif Cedex 94805 France Details
Novartis Investigative Site Sutton Surrey SM2 5PT United Kingdom Details
Novartis Investigative Site London WC1N 3JH United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field